Advertisement

Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients

Published:December 27, 2015DOI:https://doi.org/10.1016/j.clcc.2015.12.008

      Abstract

      Background

      Capecitabine is used to treat colorectal (CRC) cancer. TRIO-013, a study examining capecitabine/oxaliplatin ± lapatinib in metastatic gastro-esophageal cancer did not show increases in overall survival (OS) with lapatinib. An analysis showed concurrent proton pump inhibitor (PPI) usage negatively impacted recurrence-free survival (RFS). We retrospectively studied PPI effects on capecitabine efficacy in early stage CRC and how capecitabine adjustments impacted RFS.

      Methods

      Early stage CRC patients taking monotherapy capecitabine treated from 2008 to 2012 were reviewed for demographics, medications, toxicities, and patient outcomes.

      Results

      Of 298 identified patients, 25.8% (n = 77) received concurrent PPIs. Five-year RFS was 74% versus 83% (hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.07-3.35; P = .03) in PPI versus non-PPI patients respectively. OS was 81% versus 78%, respectively (HR, 1.13; 95% CI, 0.60-2.14; P = .7). After accounting for gender, stage, age, and performance status, PPI patients tended toward decreased RFS (HR, 1.65; 95% CI, 0.93-2.94; P = .09). Capecitabine dose modifications affected outcomes. Five-year RFS was 84% in the control group, 100% in the treatment-delay group (P = .99), 67% in the dose reduction group (HR, 2.46; 95% CI, 1.23-4.93; P = .01), and 64% in the discontinuation group (HR, 2.27; 95% CI, 0.93-5.53; P = .07). Five-year OS was significantly less in the discontinuation group than control group (59% vs. 82%; HR, 3.27; 95% CI, 1.44-7.45; P = .005).

      Conclusions

      PPIs appear to impact RFS; this may be due to PPIs preventing capecitabine tablet dissolution and absorption. Patients with dose reductions or who stopped treatment had worse outcomes than patients who continued with treatment at starting doses.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reigner B.
        • Blesch K.
        • Weidekamm E.
        Clinical pharmacokinetics of capecitabine.
        Clin Pharmacokinet. 2001; 40: 85-104
        • Koukourakis G.V.
        • Kouloulias V.
        • Koukourakis M.J.
        • Zacharias G.A.
        • Zabatis H.
        • Kouvaris J.
        Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.
        Molecules. 2008; 13: 1897-1922
        • Borner M.M.
        • Schoffski P.
        • de Wit R.
        • et al.
        Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
        Eur J Cancer. 2002; 38: 349-358
        • Liu G.
        • Franssen E.
        • Fitch M.I.
        • Warner E.
        Patient preferences for oral versus intravenous palliative chemotherapy.
        J Clin Oncol. 1997; 15: 110-115
        • Twelves C.
        • Boyer M.
        • Findlay M.
        • et al.
        Capecitabine (xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
        Eur J Cancer. 2001; 37: 597-604
        • McLeod H.L.
        • Evans W.E.
        Oral cancer chemotherapy: the promise and the pitfalls.
        Clin Cancer Res. 1999; 5: 2669-2671
        • Budha N.R.
        • Frymoyer A.
        • Smelick G.S.
        • et al.
        Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the achilles heel of targeted therapy?.
        Clin Pharmacol Ther. 2012; 92: 203-213
        • Rotermann M.
        • Sanmartin C.
        • Hennessy D.
        • Arthur M.
        Prescription medication use by Canadians aged 6 to 79.
        Health Rep. 2014; 25: 3-9
        • Smelick G.S.
        • Heffron T.P.
        • Chu L.
        • et al.
        Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.
        Mol Pharm. 2013; 10: 4055-4062
        • Van Cutsem E.
        • Verslype C.
        • Tejpar S.
        Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
        Semin Oncol. 2005; 32: 43-51
        • Scheithauer W.
        • McKendrick J.
        • Begbie S.
        • et al.
        Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
        Ann Oncol. 2003; 14: 1735-1743
        • Ha V.H.
        • Ngo M.
        • Chu M.P.
        • Ghosh S.
        • Sawyer M.B.
        • Chambers C.R.
        Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?.
        J Oncol Pharm Pract. 2015; 21: 194-200
        • Chu M.P.
        • Ghosh S.
        • Chambers C.R.
        • et al.
        Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
        Clin Lung Cancer. 2015; 16: 33-39
        • Hecht J.R.
        • Bang Y.
        • Qin S.
        • et al.
        Lapatinib in combination with capecitabine plus oxaliplatin in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: the TRIO-013/LOGiC trial.
        J Clin Oncol. 2013; 31 (Abstract LBA4001). 2013 ASCO Annual Meeting
        • Chu M.P.
        • Hecht J.R.
        • Slamon D.J.
        • et al.
        Proton pump inhibitors may impair capecitabine efficacy in advanced gastroesophageal cancer - results from TRIO-013/LOGiC trial.
        Ann Oncol. 2014; 25: iv210-iv253
        • Hofheinz R.D.
        • Heinemann V.
        • von Weikersthal L.F.
        • et al.
        Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
        Br J Cancer. 2012; 107: 1678-1683
        • Stintzing S.
        • Fischer von Weikersthal L.
        • Vehling-Kaiser U.
        • et al.
        Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
        Br J Cancer. 2011; 105: 206-211
        • Twelves C.
        • Scheithauer W.
        • McKendrick J.
        • et al.
        Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
        Ann Oncol. 2012; 23: 1190-1197
        • Reigner B.
        • Verweij J.
        • Dirix L.
        • et al.
        Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
        Clin Cancer Res. 1998; 4: 941-948
        • Reigner B.
        • Clive S.
        • Cassidy J.
        • et al.
        Influence of the antacid maalox on the pharmacokinetics of capecitabine in cancer patients.
        Cancer Chemother Pharmacol. 1999; 43: 309-315
        • Maton P.N.
        • Burton M.E.
        Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.
        Drugs. 1999; 57: 855-870
        • Sontag S.J.
        The medical management of reflux esophagitis. Role of antacids and acid inhibition.
        Gastroenterol Clin North Am. 1990; 19: 683-712
        • Rohss K.
        • Lind T.
        • Wilder-Smith C.
        Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
        Eur J Clin Pharmacol. 2004; 60: 531-539
        • Mullin J.M.
        • Gabello M.
        • Murray L.J.
        • et al.
        Proton pump inhibitors: actions and reactions.
        Drug Discov Today. 2009; 14: 647-660
        • Shin J.M.
        • Sachs G.
        Pharmacology of proton pump inhibitors.
        Curr Gastroenterol Rep. 2008; 10: 528-534
        • Chiba N.
        • De Gara C.J.
        • Wilkinson J.M.
        • Hunt R.H.
        Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.
        Gastroenterology. 1997; 112: 1798-1810
        • Sigterman K.E.
        • van Pinxteren B.
        • Bonis P.A.
        • Lau J.
        • Numans M.E.
        Short-term treatment with proton pump inhibitors, H2-receptor antagonists, and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
        Cochrane Database Syst Rev. 2013; 5: CD002095
      1. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Tarceva NDA 21–743/S000 clinical pharmacology and biopharmaceutics review [Web site]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva_biopharmr.PDF. Updated November 18, 2004. Accessed March 16, 2015.